Corcept Therapeutics
Menlo Park
About Corcept Therapeutics
Since our founding in May 1998 we have been focused on the impact of cortisol and the potential benefits of developing glucocorticoid receptor antagonists. About 80 percent of the tissues in the body have receptors for cortisol, and the effects of excess cortisol are severe and often life-threatening. Our initial research has been with mifepristone, which potently blocks the cortisol receptor. On February 17, 2012, the FDA approved Korlym® (mifepristone) in the United States as a once-daily oral medication for treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. Mifepristone is also being studied in a phase 3 trial, evaluating the impact of cortisol blockade on the psychotic features of psychotic depression. We plan to continue enrolling patients in this study throughout 2013.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 251 – 500
- Estimated revenue: $500K – $1M
- Total funding: $119.1M
- Funding stage: IPO
- Last round: Post-IPO Equity (Apr 2012)
- Ticker: nasdaq:CORT
- Website: corcept.com
- Phone: 16503273218
Industries & Categories
Biotechnology, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/corcept-therapeutics-108635 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.